de Commonwealth Equity Services BioCryst Pharmaceuticals BCRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 669 k | Comprar |
66,855
+352
| +0.5% | +USD 3.18 k | ﹤0.01% | 3056 |
|
|
2026
Q1 | USD 633 k | Vender |
66,503
-13,244
| -17% | -USD 103 k | ﹤0.01% | 3002 |
|
|
2025
Q4 | USD 622 k | Vender |
79,747
-46,312
| -37% | -USD 335 k | ﹤0.01% | 2987 |
|
|
2025
Q3 | USD 957 k | Vender |
126,059
-14,007
| -10% | -USD 117 k | ﹤0.01% | 2619 |
|
|
2025
Q2 | USD 1.26 M | Vender |
140,066
-1,056
| -0.7% | -USD 9.8 k | ﹤0.01% | 2374 |
|
|
2025
Q1 | USD 1.06 M | Comprar |
141,122
+1,990
| +1% | +USD 16.1 k | ﹤0.01% | 2408 |
|
|
2024
Q4 | USD 1.05 M | Vender |
139,132
-3,567
| -2% | -USD 27.1 k | ﹤0.01% | 2348 |
|
|
2024
Q3 | USD 1.08 M | Vender |
142,699
-1,175
| -0.8% | -USD 8.93 k | ﹤0.01% | 2285 |
|
|
2024
Q2 | USD 889 k | Vender |
143,874
-1,450
| -1% | -USD 8 k | ﹤0.01% | 2376 |
|
|
2024
Q1 | USD 738 k | Vender |
145,324
-120
| -0.1% | -USD 675 | ﹤0.01% | 2476 |
|
|
2023
Q4 | USD 871 k | Vender |
145,444
-16,640
| -10% | -USD 96.4 k | ﹤0.01% | 2271 |
|
|
2023
Q3 | USD 1.15 M | Mantener |
162,084
| – | – | ﹤0.01% | 1983 |
|
|
2023
Q2 | USD 1.14 M | Comprar |
162,084
+1,485
| +0.9% | +USD 11.9 k | ﹤0.01% | 2003 |
|
|
2023
Q1 | USD 1.34 M | Comprar |
160,599
+5,900
| +4% | +USD 56.8 k | ﹤0.01% | 1839 |
|
|
2022
Q4 | USD 1.78 M | Vender |
154,699
-12,831
| -8% | -USD 160 k | ﹤0.01% | 1580 |
|
|
2022
Q3 | USD 2.11 M | Comprar |
167,530
+170
| +0.1% | +USD 2.19 k | 0.01% | 1380 |
|
|
2022
Q2 | USD 1.77 M | Vender |
167,360
-5,932
| -3% | -USD 61.2 k | ﹤0.01% | 1506 |
|
|
2022
Q1 | USD 2.82 M | Comprar |
173,292
+2,485
| +1% | +USD 39.9 k | 0.01% | 1274 |
|
|
2021
Q4 | USD 2.36 M | Comprar |
170,807
+50,584
| +42% | +USD 669 k | 0.01% | 1389 |
|
|
2021
Q3 | USD 1.73 M | Vender |
120,223
-576
| -0.5% | -USD 9.08 k | ﹤0.01% | 1526 |
|
|
2021
Q2 | USD 1.91 M | Vender |
120,799
-2,660
| -2% | -USD 36.1 k | ﹤0.01% | 1453 |
|
|
2021
Q1 | USD 1.26 M | Comprar |
123,459
+5,004
| +4% | +USD 51.6 k | ﹤0.01% | 1639 |
|
|
2020
Q4 | USD 882 k | Vender |
118,455
-1,441
| -1% | -USD 7.43 k | ﹤0.01% | 1729 |
|
|
2020
Q3 | USD 411 k | Comprar |
119,896
+7,400
| +7% | +USD 31.7 k | ﹤0.01% | 2108 |
|
|
2020
Q2 | USD 536 k | Comprar |
112,496
+12,884
| +13% | +USD 51.5 k | ﹤0.01% | 1834 |
|
|
2020
Q1 | USD 199 k | Comprar |
99,612
+14,932
| +18% | +USD 41.1 k | ﹤0.01% | 2397 |
|
|
2019
Q4 | USD 292 k | Comprar |
84,680
+26,950
| +47% | +USD 67.8 k | ﹤0.01% | 2336 |
|
|
2019
Q3 | USD 165 k | Comprar |
57,730
+4,500
| +8% | +USD 14 k | ﹤0.01% | 2596 |
|
|
2019
Q2 | USD 201 k | Comprar |
53,230
+9,900
| +23% | +USD 59.6 k | ﹤0.01% | 2505 |
|
|
2019
Q1 | USD 352 k | Mantener |
43,330
| – | – | ﹤0.01% | 2022 |
|
|
2018
Q4 | USD 349 k | Mantener |
43,330
| – | – | ﹤0.01% | 1913 |
|
|
2018
Q3 | USD 330 k | Mantener |
43,330
| – | – | ﹤0.01% | 2088 |
|
|
2018
Q2 | USD 248 k | Vender |
43,330
-200
| -0.5% | -USD 1.1 k | ﹤0.01% | 2291 |
|
|
2018
Q1 | USD 207 k | Comprar |
43,530
+600
| +1% | +USD 3.08 k | ﹤0.01% | 2376 |
|
|
2017
Q4 | USD 211 k | Comprar |
42,930
+1,275
| +3% | +USD 6.18 k | ﹤0.01% | 2327 |
|
|
2017
Q3 | USD 218 k | Comprar |
41,655
+900
| +2% | +USD 4.61 k | ﹤0.01% | 2206 |
|
|
2017
Q2 | USD 227 k | Comprar |
40,755
+800
| +2% | +USD 4.87 k | ﹤0.01% | 2137 |
|
|
2017
Q1 | USD 336 k | Vender |
39,955
-300
| -0.7% | -USD 2.09 k | ﹤0.01% | 1776 |
|
|
2016
Q4 | USD 255 k | Mantener |
40,255
| – | – | ﹤0.01% | 1882 |
|
|
2016
Q3 | USD 178 k | Mantener |
40,255
| – | – | ﹤0.01% | 2020 |
|
|
2016
Q2 | USD 114 k | Comprar |
40,255
+5,450
| +16% | +USD 16.9 k | ﹤0.01% | 2082 |
|
|
2016
Q1 | USD 98 k | Comprar |
34,805
+5,300
| +18% | +USD 23.5 k | ﹤0.01% | 2058 |
|
|
2015
Q4 | USD 304 k | Comprar |
29,505
+3,800
| +15% | +USD 37.8 k | ﹤0.01% | 1597 |
|
|
2015
Q3 | USD 293 k | Comprar |
25,705
+800
| +3% | +USD 10.7 k | ﹤0.01% | 1558 |
|
|
2015
Q2 | USD 372 k | Vender |
24,905
-320
| -1% | -USD 3.64 k | ﹤0.01% | 1508 |
|
|
2015
Q1 | USD 228 k | Comprar |
25,225
+50
| +0.2% | +USD 518 | ﹤0.01% | 1810 |
|
|
2014
Q4 | USD 306 k | Vender |
25,175
-3,320
| -12% | -USD 36.7 k | ﹤0.01% | 1562 |
|
|
2014
Q3 | USD 279 k | Vender |
28,495
-62,028
| -69% | -USD 760 k | ﹤0.01% | 1597 |
|
|
2014
Q2 | USD 1.15 M | Comprar |
90,523
+47,200
| +109% | +USD 459 k | 0.01% | 792 |
|
|
2014
Q1 | USD 458 k | Comprar |
43,323
+24,300
| +128% | +USD 259 k | 0.01% | 1226 |
|
|
2013
Q4 | USD 145 k | Vender |
19,023
-250
| -1% | -USD 1.58 k | ﹤0.01% | 1769 |
|
|
2013
Q3 | USD 140 k | Comprar |
19,273
+2,650
| +16% | +USD 13.4 k | ﹤0.01% | 1713 |
|
|
2013
Q2 | USD 26 k | Comprar |
+16,623
| Nuevas | +USD 28.7 k | ﹤0.01% | 1773 |
|
Otros fondos que tienen BCRX en su cartera
Posición de Commonwealth Equity Services en BCRX: resumen de T2 2026
Commonwealth Equity Services aumentó su participación en BioCryst Pharmaceuticals (BCRX) en 0.53% durante T2 2026, al comprar aproximadamente USD 3.18 k y elevar la posición a 66,855 acciones con un valor de USD 669 k. La posición representa ﹤0.01% de la cartera y ocupa el puesto #3056.
Commonwealth Equity Services reportó por primera vez una posición en BCRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 2.82 M en T1 2022. Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank mantienen una posición en BCRX.
- Al cierre de T2 2026, Commonwealth Equity Services tenía 66,855 acciones de BioCryst Pharmaceuticals con un valor de USD 669 k.
- Commonwealth Equity Services compró 352 acciones de BioCryst Pharmaceuticals en T2 2026, por un monto estimado de USD 3.18 k.
- BioCryst Pharmaceuticals representó ﹤0.01% de la cartera de Commonwealth Equity Services en T2 2026 y fue su posición número 3056.
- Commonwealth Equity Services reportó por primera vez una posición en BioCryst Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de Commonwealth Equity Services en BioCryst Pharmaceuticals alcanzó su máximo de USD 2.82 M en T1 2022.
- Al cierre de T2 2026, 319 fondos que sigue Wall St. Rank tenían BioCryst Pharmaceuticals en cartera.
Según el Informe 13F de Commonwealth Equity Services correspondiente a T2 2026, presentado el 29 jul 2026.